A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract

Area of Science:

• Immunology
• Allergy and Clinical Immunology
• Pharmacology

Background:

• Clinically effective cat allergen immunotherapy (AIT) uses doses of approximately 15 microg of Fel d 1.
• Current US AIT practices often utilize lower maintenance doses than those proven effective.
• Determining optimal Fel d 1 dosage is crucial for effective AIT.

Purpose of the Study:

• To compare the immunologic efficacy of lower Fel d 1 doses (0.6 microg and 3.0 microg) versus placebo.
• To assess if 0.6 microg or 3.0 microg Fel d 1 doses are as effective as the 15.0 microg dose.
• To evaluate immunologic parameters as outcomes for AIT efficacy.

Main Methods:

• Double-blind, placebo-controlled study with 28 cat-allergic patients.
• Groups received placebo, 0.6 microg, 3.0 microg, or 15.0 microg Fel d 1 extract.
• Immunologic responses assessed via skin prick tests, serum IgE/IgG4, nasal challenges, cytokine measurements (IL-4, IL-5, IFN-gamma), and lymphocyte proliferation.

Main Results:

• Significant dose-dependent improvements observed in skin prick tests and cat-specific IgG4 levels with higher doses.
• The 0.6 microg Fel d 1 dose showed no significant difference compared to placebo.
• Only the 15.0 microg Fel d 1 dose significantly reduced CD4+/IL-4+ peripheral blood mononuclear cells (PBMCs), a marker linked to clinical response.

Conclusions:

• A maintenance dose of 15.0 microg Fel d 1 demonstrated the most consistent immunologic response in AIT.
• The 3.0 microg dose improved some markers but did not significantly reduce CD4+/IL-4+ PBMCs.
• Findings suggest 15.0 microg Fel d 1 is optimal for achieving clinically significant AIT outcomes.